Itolizumab

Itolizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	CD6
Clinical data
Trade names	Alzumab
ATC code	none;
Legal status
Legal status	Approved in India;
Identifiers
CAS Number	1116433-11-4 ;
ChemSpider	none;
UNII	XQQ2RHV14N;
	(what is this?) (verify)

Itolizumab (INN, trade name Alzumab) is a ‘first in class’ humanized IgG1 monoclonal antibody developed by Biocon[1] and the Center of Molecular Immunology (CIM), Havana.[2]

Mechanism of action

It selectively targets CD6, a pan T cell marker involved in co-stimulation, adhesion and maturation of T cells. Itolizumab, by binding to CD6, down regulates T cell activation, causes reduction in synthesis of pro-inflammatory cytokines and possibly plays an important role by reducing T cell infiltration at sites of inflammation.[3]

Clinical trials

A double blind, placebo controlled, phase III treat –Plaq study of itolizumab successfully met the pre-specified primary end-point of significant improvement in PASI-75 (Psoriasis Area and Severity Index) score after 12 weeks of treatment in patients with moderate to severe psoriasis compared to placebo.[4]

Applications

Biocon received marketing authorization for the drug from the Drugs Controller General of India (DCGI) in January 2013 and marketing within India commenced in August 2013.[1][5]

In July 2020, Biocon received authorization in India for its use in the treatment of COVID-19.[6]

gollark: It is a very efficient game.

gollark: You can overclock them... all the way to an amazing 2GHz, which leaves it massively slower than a 10-year-old desktop.

gollark: Pis are entirely capable for things like webservers, but not compute-heavy workloads like Minecraft *somehow* is.

gollark: Correction: Cortex-A72s.

gollark: The server here runs on an actual high-power... server... with 4 Neoverse-N1 cores, lots of fast RAM, etc. Raspberry Pis have 8GB of RAM at most, and it's slower LPDDR4, and it has half the clocks, and Cortex-A73s, which are worse.

References

Jayaramun, Killugudi (December 2013). "Biocon's first-in-class anti-CD6 mAb reaches the market". Nat. Biotechnol. 31 (12). United Kingdom. pp. 1062–3.
"India prepares to test Itolizumab, the drug credited for lowering Covid mortality in Cuba". May 30, 2020.
http://www.biocon.com/docs/PR_080113.pdf?subLink=news
Urs, Anil. "Biocon's test shows positive results for Itolizumab". @businessline.
"Biocon's psoriasis drug, Itolizumab receives DCGI marketing authorization". Pharmabiz.com. India: Saffron Media. January 8, 2013.
Jul 2020, ET Online | 13; Ist, 08:11 Pm. "Biocon's Itolizumab approved for COVID-19 treatment: All you need to know". The Economic Times. Retrieved 2020-07-14.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[jayaraman2013-1] Jayaramun, Killugudi (December 2013). "Biocon's first-in-class anti-CD6 mAb reaches the market". Nat. Biotechnol. 31 (12). United Kingdom. pp. 1062–3.

[2] "India prepares to test Itolizumab, the drug credited for lowering Covid mortality in Cuba". May 30, 2020.

[3] ttp://www.biocon.com/docs/PR_080113.pdf?subLink=news

[4] Urs, Anil. "Biocon's test shows positive results for Itolizumab". @businessline.

[5] "Biocon's psoriasis drug, Itolizumab receives DCGI marketing authorization". Pharmabiz.com. India: Saffron Media. January 8, 2013.

[6] Jul 2020, ET Online | 13; Ist, 08:11 Pm. "Biocon's Itolizumab approved for COVID-19 treatment: All you need to know". The Economic Times. Retrieved 2020-07-14.